A nerve conduction test may help to diagnose Charcot-Marie-Tooth disease type X (CMTX) patients with neurologic episodes more common to diseases of the central nervous system. The study, “The Electrophysiological Features in X-Linked Charcot-Marie-Tooth Disease With Transient Central Nervous System Deficits,” was published in the journal…
A new study has evaluated and identified the best tests to use as outcome measures, which help doctors track patient progress or deterioration, for those with Charcot-Marie-Tooth disease type 1A. The study’s goal was to determine which outcome measures can help improve disease…
Pharnext recently provided an update from its ongoing Phase 3 clinical trials evaluating PXT3003 for treating Charcot-Marie-Tooth disease type 1A (CMT1A) in adults, and also announced that some top-line results are expected by October 2018. PXT3003 is a fixed-dose combination of baclofen, naltrexone and sorbitol with orphan…
Grünenthal, the Lead Discovery Center (LDC) and the Max-Planck Society have signed a research collaboration agreement to develop new therapies for Charcot-Marie-Tooth type 1A (CMT1A). Two branches of Max-Planck are involved: Max-Planck Innovation and the Max Planck Institute of Experimental Medicine (MPI-EM). These two will work with…
Charcot-Marie-Tooth (CMT) disease type 4C is the most common recessive form of the disease in Norway. Researchers, looking at all known Norwegian patients with CMT4C, also found six new mutations that cause the disease. The study, “…
A proposed therapy for neurodegenerative diseases involving the removal of the neurofilament light chain protein (NEFL) may have harmful consequences in humans, potentially leading to Charcot-Marie-Tooth disease (CMT), researchers have found. The research team discovered this while studying the effects of a type of mutation in the NEFL gene,…
Flex Pharma is terminating a Phase 2 clinical trial that was assessing FLX-787 as a potential treatment for muscle cramps in Charcot-Marie-Tooth disease (CMT) patients due to concerns about the oral tolerability of the investigational therapy. The randomized, double-blind COMMIT trial (NCT03254199) was being conducted at 20…
The French biopharmaceutical company Pharnext recently announced that its candidate for the treatment of Charcot-Marie-Tooth disease type 1A (CMT1A) was granted priority review by the China Food and Drug Administration (CFDA). PXT3003 is a fixed-dose combination of baclofen, naltrexone, and sorbitol. The therapy candidate has received orphan drug status in both…
Treatment with the chemotherapy drug vincristine can lead to severe neuropathy (nerve disease) in patients with an underlying mutation for Charcot-Marie-Tooth disease type 4, according to a new case report from California. The study, “Heterozygosity for CMT Type 4 Predicts a Severe Vincristine-induced Polyneuropathy Phenotype: A Case Report…
TRPV4 channels, critical players in Charcot-Marie-Tooth disease type 2C (CMT2C), regulate the structure and function of mitochondria in diverse cell types, a new study shows. The study, “TRPV4 interacts with mitochondrial proteins and acts as a mitochondrial structure-function regulator,” appeared in bioRxiv. The balance of calcium (Ca2+)…
Get regular updates to your inbox.